C H Chung1, J Aulino2, N J Muldowney3, H Hatakeyama4, J Baumann4, B Burkey5, J Netterville5, R Sinard5, W G Yarbrough6, A J Cmelak7, R J Slebos8, Y Shyr9, J Parker10, J Gilbert4, B A Murphy4. 1. Division of Hematology/Oncology, Department of Medicine; Department of Cancer Biology, Vanderbilt University School of Medicine; Vanderbilt-Ingram Comprehensive Cancer Center. Electronic address: Christine.Chung@Vanderbilt.edu. 2. Department of Radiology. 3. Vanderbilt-Ingram Comprehensive Cancer Center. 4. Division of Hematology/Oncology, Department of Medicine. 5. Department of Otolaryngology. 6. Department of Cancer Biology, Vanderbilt University School of Medicine; Vanderbilt-Ingram Comprehensive Cancer Center; Department of Otolaryngology. 7. Department of Radiation Oncology. 8. Department of Cancer Biology, Vanderbilt University School of Medicine. 9. Department of Biostatistics, Vanderbilt University School of Medicine, Nashville, TN. 10. Expression Analysis, Inc., Durham, NC, USA.
Abstract
BACKGROUND: Our previous study has shown that nuclear factor-kappa B (NF-kappaB)-signaling pathway was associated with a higher rate of recurrence in head and neck squamous cell carcinoma (HNSCC). The combination of bortezomib, an NF-kappaB inhibitor by inhibition of proteasomes, plus docetaxel was assessed for efficacy and toxicity. MATERIALS AND METHODS: Patients with recurrent and/or metastatic HNSCC were enrolled on a phase II bortezomib/docetaxel trial (bortezomib 1.6 mg/m(2) and docetaxel 40 mg/m(2) on days 1 and 8 of a 21-day cycle). Response was assessed using RECIST. Tissue specimens were evaluated for the presence of human papillomavirus (HPV) and expression of NF-kappaB-associated genes. RESULTS: Twenty-one of 25 enrolled patients were assessable for response; one partial response (PR, 5%), 10 stable disease (SD, 48%) and 10 progressive disease (PD, 48%). Patients with PR/SD had significantly longer survival compared with patients with PD and the regimen was well tolerated. Only one of 20 tumors was positive for HPV. Patients with PD had higher expression of NF-kappaB and epidermal growth factor receptor-associated genes in their tumors by gene expression analysis. CONCLUSION: Further understanding of treatment resistance and interactions between bortezomib and docetaxel may provide novel approaches in managing HNSCC.
BACKGROUND: Our previous study has shown that nuclear factor-kappa B (NF-kappaB)-signaling pathway was associated with a higher rate of recurrence in head and neck squamous cell carcinoma (HNSCC). The combination of bortezomib, an NF-kappaB inhibitor by inhibition of proteasomes, plus docetaxel was assessed for efficacy and toxicity. MATERIALS AND METHODS:Patients with recurrent and/or metastatic HNSCC were enrolled on a phase II bortezomib/docetaxel trial (bortezomib 1.6 mg/m(2) and docetaxel 40 mg/m(2) on days 1 and 8 of a 21-day cycle). Response was assessed using RECIST. Tissue specimens were evaluated for the presence of human papillomavirus (HPV) and expression of NF-kappaB-associated genes. RESULTS: Twenty-one of 25 enrolled patients were assessable for response; one partial response (PR, 5%), 10 stable disease (SD, 48%) and 10 progressive disease (PD, 48%). Patients with PR/SD had significantly longer survival compared with patients with PD and the regimen was well tolerated. Only one of 20 tumors was positive for HPV. Patients with PD had higher expression of NF-kappaB and epidermal growth factor receptor-associated genes in their tumors by gene expression analysis. CONCLUSION: Further understanding of treatment resistance and interactions between bortezomib and docetaxel may provide novel approaches in managing HNSCC.
Authors: Arlene A Forastiere; Helmuth Goepfert; Moshe Maor; Thomas F Pajak; Randal Weber; William Morrison; Bonnie Glisson; Andy Trotti; John A Ridge; Clifford Chao; Glen Peters; Ding-Jen Lee; Andrea Leaf; John Ensley; Jay Cooper Journal: N Engl J Med Date: 2003-11-27 Impact factor: 91.245
Authors: S B Horwitz; L Lothstein; J J Manfredi; W Mellado; J Parness; S N Roy; P B Schiff; L Sorbara; R Zeheb Journal: Ann N Y Acad Sci Date: 1986 Impact factor: 5.691
Authors: J Adams; V J Palombella; E A Sausville; J Johnson; A Destree; D D Lazarus; J Maas; C S Pien; S Prakash; P J Elliott Journal: Cancer Res Date: 1999-06-01 Impact factor: 12.701
Authors: R M Resnick; M T Cornelissen; D K Wright; G H Eichinger; H S Fox; J ter Schegget; M M Manos Journal: J Natl Cancer Inst Date: 1990-09-19 Impact factor: 13.506
Authors: Jill Gilbert; Anthony Cmelak; Yu Shyr; James Netterville; Brian B Burkey; Robert J Sinard; Wendall G Yarbrough; Christine H Chung; Joseph M Aulino; Barbara A Murphy Journal: Cancer Date: 2008-07-01 Impact factor: 6.860
Authors: G Catimel; J Verweij; V Mattijssen; A Hanauske; M Piccart; J Wanders; H Franklin; N Le Bail; M Clavel; S B Kaye Journal: Ann Oncol Date: 1994-07 Impact factor: 32.976
Authors: Tetyana V Bagnyukova; Ilya G Serebriiskii; Yan Zhou; Elizabeth A Hopper-Borge; Erica A Golemis; Igor Astsaturov Journal: Cancer Biol Ther Date: 2010-11-01 Impact factor: 4.742
Authors: Athanassios Argiris; Austin G Duffy; Shivaani Kummar; Nicole L Simone; Yoshio Arai; Seungwon W Kim; Susan F Rudy; Vishnu R Kannabiran; Xinping Yang; Minyoung Jang; Zhong Chen; Nanette Suksta; Theresa Cooley-Zgela; Susmita G Ramanand; Aarif Ahsan; Mukesh K Nyati; John J Wright; Carter Van Waes Journal: Clin Cancer Res Date: 2011-07-12 Impact factor: 12.531
Authors: Hilary S Parker; Jeffrey T Leek; Alexander V Favorov; Michael Considine; Xiaoxin Xia; Sameer Chavan; Christine H Chung; Elana J Fertig Journal: Bioinformatics Date: 2014-06-06 Impact factor: 6.937